Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(RULE 13D-101)
Under the Securities Exchange Act of 1934
(Amendment No. 5)
Cytomedix, Inc
(Name of Issuer)
Common Stock
(Title of Class of Securities)
23283B204
(CUSIP Number)
Edward T Isleib, 1600 Rockcliff Road, Austin, TX 78746
(512)328-4932
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 14, 2005
(Date of Event which Requires Filing of the
Statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition that is the
subject of this Schedule 13D, and is filing this
schedule because of 240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box.
Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule,
including all exhibits. See 240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form
with respect to the subject class of securities, and
for any subsequent amendment containing information
which would alter disclosures provided in a prior cover
page.
The information required on the remainder of this cover
page shall not be deemed to be "filed" for the purpose
of Section 18 of the Securities of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to
the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however,
see the Notes).
SCHEDULE 13D
CUSIP No. 23283B204
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons
(entities only).
Michael Marcus
2. Check the Appropriate Box if a Member of a
Group (See Instructions)
a. N/A
b.
_______________________________________________________
3. SEC Use Only
_______________________________________________________
4. Source of Funds (See Instructions) PF
_______________________________________________________
5. Check if Disclosure of Legal Proceedings Is
Required Pursuant to Items 2(d) or 2(e) N/A
_______________________________________________________
6. Citizenship or Place of Organization
U.S.
_______________________________________________________
7. Sole Voting Power 1,388,500
Number of (See Item 5 (i) below)
Shares Bene- ________________________________________
ficially by 8. Shared Voting Power
Owned by Each ________________________________________
Reporting 9. Sole Dispositive Power 1,388,500
Person With (See Item 5 (i) below)
________________________________________
10. Shared Dispositive Power
_______________________________________________________
11. Aggregate Amount Beneficially Owned by
Each Reporting Person 1,388,500
(See Item 5 (i) below)
_______________________________________________________
12. Check if the Aggregate Amount in Row (11)
Excludes Certain Shares
_______________________________________________________
13. Percent of Class Represented by Amount in Row
(11) 5.58% (See Item 5 (i) below)
_______________________________________________________
14. Type of Reporting Person (See Instructions)
IN
_______________________________________________________
ITEM 1. SECURITY AND ISSUER
The class of equity securities to which this Schedule 13D
relates to the Common Stock, $.001 par value of
Cytomedix, Inc., a Delaware Corporation (the Issuer).
Its principal executive offices are located in Little
Rock, Arkansas.
ITEM 2. IDENTITY AND BACKGROUND
The person filing this statement is Michael P. Marcus.
Mr. Marcus is a U.S. citizen. The address of Mr. Marcus
is 1600 Rockcliff Road, Austin, TX 78746. Mr. Marcus'
principal occupation is as an Investor.
During the last five years, Mr. Marcus has not been a
party to a civil proceeding (excluding traffic violations
or similar misdemeanors).
During the past five years, Mr. Marcus has not been a
party to a civil proceeding of a judicial or
administrative body as a result of which a judgment,
decree, or final order has been issued enjoining future
violations of, or prohibiting or mandating activities
subject to, United States federal or state securities
laws or finding any violation with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER
CONSIDERATION.
The source of all funds used for the purchase of the
securities identified herein was personal funds.
ITEM 4. PURPOSE OF TRANSACTION
The securities identified herein have been acquired by
Mr. Marcus solely for investment purposes.
ITEM 5. INTEREST IN SECURITY OF THE ISSUER.
(i) Includes 1,188,500 shares of Common Stock and
200,000 Warrants Convertible into Common Stock.
Pursuant to the terms of the Warrants the Reporting
Persons cannot be the "beneficial owners" of more than
9.99% of the Common Stock within the meaning of Rule
13d-1 of the Securities Exchange Act of 1934.
(ii) Mr. Marcus has the sole power to vote and dispose
of the shares of common stock identified in paragraph
(a) above.
(iii) Changes in the percent of ownership of the common
stock are due to the sale of stock by Mr. Marcus.
No other person is known to have the right to receive
or the power to direct the receipt of dividends from,
or the proceeds from the sale of, shares owned by Mr.
Marcus.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS, OR
RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.
None.
ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.
None.
AFTER REASONABLE INQUIRY AND TO THE BEST OF MY
KNOWLEDGE AND BELIEF, I CERTIFY THAT THE INFORMATION
SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND
CORRECT.
DATED: April 20, 2005 /S/ Michael P. Marcus
_______________________
Michael P. Marcus